Literature DB >> 21980963

Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.

Chen Bing1, Cao Xiaomeia, Li Jinhenga.   

Abstract

BACKGROUND: The aim of this study was to elucidate the gene dose effect of NAT2 and the effect on the pharmacokinetics of isoniazid (INH) and its metabolites acetylisoniazid (AcINH) in Chinese subjects.
METHODS: A total of 24 healthy Chinese subjects, consisting of eight homozygous wild types (wt/wt), eight heterozygous mutants (m/wt) and eight homozygous mutants (m/m) for NAT2, were enrolled in the study. The blood samples (0-14 h) of the subjects were taken after oral administration of a single dose (300 mg) of INH. Concentrations of INH and AcINH in plasma were measured by a reversed-phase HPLC method.
RESULTS: The ratio of AcINH and INH (R(A/I)) 3 h post-dose of wt/wt, m/wt and m/m groups were 3.22 ± 1.34, 1.35 ± 0.20 and 0.22 ± 0.06, respectively (p<0.01). The area under concentration-time curve (AUC) values of three groups were 10.35 ± 2.12, 16.34 ± 3.05, 42.24 ± 8.51 mg/h/L for INH and 42.19 ± 8.80, 38.05 ± 5.32, 19.78 ± 3.72 mg/h/L for AcINH, respectively (p<0.01). There was a good linear relationship between pharmacokinetic parameters and the number of active NAT2 genes.
CONCLUSIONS: The results suggest that there is a conspicuous gene dose effect in the pharmacokinetics of INH and AcINH. This finding may be valuable in the personalized therapy of tuberculosis with INH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21980963     DOI: 10.1515/DMDI.2011.016

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN: 0792-5077


  8 in total

1.  N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies.

Authors:  Liang Zhang; Zhaolan Xiang; Rui Hao; Ru Li; Yi Zhu
Journal:  Tumour Biol       Date:  2013-12-13

Review 2.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

3.  A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.

Authors:  Henrik Cordes; Christoph Thiel; Hélène E Aschmann; Vanessa Baier; Lars M Blank; Lars Kuepfer
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.

Authors:  Mark A Doll; Raúl A Salazar-González; Srineil Bodduluri; David W Hein
Journal:  Acta Pharm Sin B       Date:  2017-06-07       Impact factor: 11.413

5.  A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.

Authors:  Christoph Thiel; Henrik Cordes; Lorenzo Fabbri; Hélène Eloise Aschmann; Vanessa Baier; Ines Smit; Francis Atkinson; Lars Mathias Blank; Lars Kuepfer
Journal:  PLoS Comput Biol       Date:  2017-02-02       Impact factor: 4.475

6.  Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation.

Authors:  Henrik Cordes; Christoph Thiel; Vanessa Baier; Lars M Blank; Lars Kuepfer
Journal:  NPJ Syst Biol Appl       Date:  2018-02-26

7.  Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid.

Authors:  Christopher Trent Brewer; Kiran Kodali; Jing Wu; Timothy I Shaw; Junmin Peng; Taosheng Chen
Journal:  Cells       Date:  2020-07-09       Impact factor: 6.600

8.  Improved genotyping of N-acetyltransferase 2: role of the ultra-slow acetylators.

Authors:  Meinolf Blaszkewicz
Journal:  EXCLI J       Date:  2013-12-05       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.